Buy Rating for Pyxis Oncology Driven by Promising Preclinical Data and Upcoming Clinical Updates

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Pyxis Oncology (PYXS – Research Report) today and set a price target of $5.00.

Swayampakula Ramakanth has given his Buy rating due to a combination of factors, including Pyxis Oncology’s promising preclinical data and upcoming clinical updates. The company’s lead candidate, micvotabart pelidotin (MICVO), has shown significant anti-tumor activity in various solid tumor models, particularly in head and neck cancer, which aligns with previous positive Phase 1 results. Additionally, the combination of MICVO with pembrolizumab has demonstrated enhanced tumor inhibition and survival benefits in preclinical studies, suggesting potential synergistic effects.
Furthermore, Pyxis Oncology is expected to release important clinical updates in the second half of 2025, which could serve as major catalysts for the company’s stock. These updates include results from the ongoing Phase 1 study in relapsed/metastatic head and neck cancer and the Phase 1/2 study of MICVO in combination with pembrolizumab in advanced solid tumors. The financial outlook, supported by a substantial cash reserve, and a risk-adjusted net present value analysis contribute to the Buy rating, with a 12-month price target of $5.00 per share.